CASI Pharmaceuticals, Inc. (CASI)

Market Cap	31.14M
Revenue (ttm)	31.56M
Net Income (ttm)	-46.89M
Shares Out	15.49M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,475
Open	2.060
Previous Close	2.090
Day's Range	2.010 - 2.110
52-Week Range	1.091 - 7.500
Beta	0.72
Analysts	Strong Buy
Price Target	4.00 (+99.01%)
Earnings Date	Nov 13, 2025

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company’s hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-FcγRIIB antib...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 1996
• Employees: 233
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI
• Website: https://www.casipharmaceuticals.com

Financial Performance

In 2024, CASI Pharmaceuticals's revenue was $28.54 million, a decrease of -15.77% compared to the previous year's $33.88 million. Losses were -$39.26 million, 45.6% more than in 2023.

Analyst Summary

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(99.01% upside)

Analyst Consensus: Strong Buy